Positive Results Reported From Phase II/III Rylaze Trial
Jazz Pharmaceuticals recently announced positive results from a phase II/III trial, developed and conducted in close collaboration with the Children's Oncology Group, evaluating the IM administration of Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) in adult and pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who have developed hypersensitivity to an Escherichia coli–derived asparaginase. Read more.

Prior Pediatric COVID-19 Infections and Low Omicron Immunity Linked
Findings from a study published in the journal Nature Communications suggests that cross-reactive immunity against the Omicron variant is low among pediatric patients with prior COVID-19 infection or multisystem inflammatory syndrome in children. Learn more about the importance of vaccinating children and younger adolescents, even with preexisting antibody immunity by an earlier SARS-CoV-2 strain.

FDA Approves Dupixent for Pediatric Patients With Moderate-to-Severe Atopic Dermatitis
The FDA recently approved Dupixent (dupilumab) for pediatric patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Learn more about this first biologic approved to treat patients from infancy to adulthood.